Gibran Nicole, Luterman Arnold, Herndon David, Lozano Daniel, Greenhalgh David G, Grubbs Lisa, Schofield Neil, Hantak Edith, Callahan Janice D, Schiestl Nina, Riina Louis H
University of Washington Burn Center, Seattle, Washington, USA.
J Burn Care Res. 2007 May-Jun;28(3):401-8. doi: 10.1097/BCR.0B013E318053D389.
We undertook a multicenter, randomized, controlled, phase 1/2 clinical study to investigate the safety and efficacy of a fibrin sealant containing 4 IU/ml thrombin (FS 4IU) for the attachment of autologous sheet grafts in patients with deep partial-thickness or full-thickness burn wounds. Fibrin sealant (FS 4IU) was compared with staples for adherence of sheet grafts in 40 patients. Patients had to have burn wounds measuring 40% TBSA or less with two comparable test sites measuring between 1% and 4% TBSA each. Wound beds were prepared before treatment assignment, which was randomized. Percent area of hematoma/seroma at Day 1 (P = .0138) and questionable viability at Day 5 (P = .0182) were significantly less for FS 4IU-treated sites. Median percent area of graft survival on Day 14 was 100% for both treatments (P = .3525). The percentage of completely closed sites generally was greater for FS 4IU-sites on Days 5 to 91; the maximum difference occurred at Day 28 (79.5% vs 59%; P = .0215). The safety profile of FS 4IU was excellent as indicated by the lack of any related serious adverse experiences. These findings indicate that FS 4IU is safe and effective for fixation of skin grafts, with outcomes similar to or better than staple fixation. The data suggest that FS 4IU is a promising candidate for further clinical studies focusing on skin graft adhesion and burn wound healing.
我们开展了一项多中心、随机、对照的1/2期临床研究,以调查含4 IU/ml凝血酶的纤维蛋白密封剂(FS 4IU)用于深Ⅱ度或全层烧伤创面自体皮片附着的安全性和有效性。在40例患者中,比较了纤维蛋白密封剂(FS 4IU)和吻合钉用于皮片黏附的情况。患者烧伤创面面积必须≤40%总体表面积(TBSA),且有两个面积在1%至4% TBSA之间的可比测试部位。在随机分配治疗前准备创面床。FS 4IU治疗部位在第1天的血肿/血清肿面积百分比(P = 0.0138)和第5天的可疑存活情况(P = 0.0182)显著更低。两种治疗在第14天的移植皮片存活面积百分比中位数均为100%(P = 0.3525)。在第5至91天,FS 4IU治疗部位完全闭合部位的百分比通常更高;最大差异出现在第28天(79.5%对59%;P = 0.0215)。由于缺乏任何相关严重不良事件,FS 4IU的安全性良好。这些发现表明,FS 4IU用于皮肤移植固定安全有效,其结果与吻合钉固定相似或更好。数据表明,FS 4IU是进一步聚焦皮肤移植黏附和烧伤创面愈合临床研究的有前景候选药物。